Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Publication/Presentation Date
6-21-2022
Abstract
Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths annually. EBV is also the etiological agent of infectious mononucleosis and is linked to multiple sclerosis and rheumatoid arthritis. Thus, an EBV vaccine would have a significant global health impact. EBV is orally transmitted and has tropism for epithelial and B cells. Therefore, a vaccine would need to prevent infection of both in the oral cavity. Passive transfer of monoclonal antibodies against the gH/gL glycoprotein complex prevent experimental EBV infection in humanized mice and rhesus macaques, suggesting that gH/gL is an attractive vaccine candidate. Here, we evaluate the immunogenicity of several gH/gL nanoparticle vaccines. All display superior immunogenicity relative to monomeric gH/gL. A nanoparticle displaying 60 copies of gH/gL elicits antibodies that protect against lethal EBV challenge in humanized mice, whereas antibodies elicited by monomeric gH/gL do not. These data motivate further development of gH/gL nanoparticle vaccines for EBV.
Volume
3
Issue
6
First Page
100658
Last Page
100658
ISSN
2666-3791
Published In/Presented At
Malhi, H., Homad, L. J., Wan, Y. H., Poudel, B., Fiala, B., Borst, A. J., Wang, J. Y., Walkey, C., Price, J., Wall, A., Singh, S., Moodie, Z., Carter, L., Handa, S., Correnti, C. E., Stoddard, B. L., Veesler, D., Pancera, M., Olson, J., King, N. P., … McGuire, A. T. (2022). Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. Cell reports. Medicine, 3(6), 100658. https://doi.org/10.1016/j.xcrm.2022.100658
Disciplines
Medicine and Health Sciences
PubMedID
35705092
Department(s)
Medical Education
Document Type
Article